日本の特発性肺線維症治療市場レポート：薬剤クラス別、エンドユーザー別、地域別、2025年～2033年

日本の特発性肺線維症治療の市場規模は2024年に1億8,100万米ドルに達しました。今後、IMARC Groupは、市場は2033年までに3億4,500万米ドルに達し、2025年から2033年にかけて7.4%の成長率（CAGR）を示すと予測しています。

本レポートで扱う主な質問

• 日本の特発性肺線維症治療市場はこれまでどのように推移し、今後どのように推移するのか？
• COVID-19が日本の特発性肺線維症治療市場に与えた影響は？
• 主要な地域市場とは？
• 薬剤クラス別の市場内訳は？
• エンドユーザー別の市場内訳は？
• 業界のバリューチェーンにおける様々な段階とは？
• 業界の主要な促進要因と課題は何か？
• 日本の特発性肺線維症治療市場の構造と主要プレーヤーは？
• 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
• 市場推定
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 日本の特発性肺線維症治療市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：薬剤クラス別

• MAPK阻害剤
• チロシン阻害剤
• オートタキシン阻害剤

第7章 市場内訳：エンドユーザー別

• 病院
• 長期ケア施設
• その他

第8章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第9章 バリューチェーン分析

第10章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第11章 価格分析

第12章 政策と規制状況

第13章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル

List of Figures

• Figure 1: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Major Drivers and Challenges
• Figure 2: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019-2024
• Figure 3: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 4: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2024
• Figure 5: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2024
• Figure 6: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Region (in %), 2024
• Figure 7: Japan: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 8: Japan: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 9: Japan: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 10: Japan: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 11: Japan: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 12: Japan: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 13: Japan: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 14: Japan: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 15: Japan: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 16: Japan: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 17: Japan: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 18: Japan: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 19: Japan: Idiopathic Pulmonary Fibrosis Treatment Industry: SWOT Analysis
• Figure 20: Japan: Idiopathic Pulmonary Fibrosis Treatment Industry: Value Chain Analysis
• Figure 21: Japan: Idiopathic Pulmonary Fibrosis Treatment Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights, 2024 and 2033
• Table 2: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
• Table 3: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by End User (in Million USD), 2025-2033
• Table 4: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Competitive Structure
• Table 5: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Key Players

The Japan idiopathic pulmonary fibrosis treatment market size reached USD 181.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 345.0 Million by 2033, exhibiting a growth rate (CAGR) of 7.4% during 2025-2033.

Idiopathic pulmonary fibrosis (IPF) is a form of chronic interstitial pneumonia characterized by the thickening and scarring of lung tissue. The clinical symptoms of IPF include breathing difficulties, persistent dry cough, fatigue, loss of appetite, and swollen limbs. It is diagnosed through blood tests, chest X-ray, computer tomography (CT) scan, lung biopsy, and pulmonary function tests. IPF is treated by prescribing anti-fibrotic drugs, which slows the rate at which the scar tissues are formed and controls the symptoms associated with the disease. Supportive therapeutic options, including pulmonary rehabilitation, palliative care, and supplemental oxygen therapy, are also provided as the effective treatment plan for IPF.

Japan Idiopathic Pulmonary Fibrosis Treatment Market Trends:

The increasing prevalence of fibrotic diseases, especially in the geriatric population, is primarily fueling the IPF treatment market growth across Japan. This can be attributed to a rise in the consumption of nicotine-based products, a surge in pollution levels, and rising stress levels. Other than this, increasing health consciousness and rising awareness regarding the effective prevention and management strategies of IPF are acting as growth-inducing factors. Other factors, such as extensive research and development (R&D) activities for introducing novel therapies, and advancements in the existing healthcare infrastructure, are positively influencing the market growth across the country.

Key Market Segmentation:

Breakup by Drug Class:

• MAPK Inhibitors
• Tyrosine Inhibitors
• Autotaxin Inhibitors

Breakup by End User:

• Hospitals
• Long-term Care Facilities
• Others

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Key Questions Answered in This Report:

• How has the Japan idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan idiopathic pulmonary fibrosis treatment market?
• What are the key regional markets?
• What is the breakup of the market based on the drug class?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the Japan idiopathic pulmonary fibrosis treatment market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Japan Idiopathic Pulmonary Fibrosis Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Class

• 6.1 MAPK Inhibitors
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Tyrosine Inhibitors
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Autotaxin Inhibitors
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by End User

• 7.1 Hospitals
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Long-term Care Facilities
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 SWOT Analysis

• 8.1 Overview
• 8.2 Strengths
• 8.3 Weaknesses
• 8.4 Opportunities
• 8.5 Threats

9 Value Chain Analysis

10 Porters Five Forces Analysis

• 10.1 Overview
• 10.2 Bargaining Power of Buyers
• 10.3 Bargaining Power of Suppliers
• 10.4 Degree of Competition
• 10.5 Threat of New Entrants
• 10.6 Threat of Substitutes

11 Price Analysis

12 Policy and Regulatory Landscape

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players